REQUITE
Validating predictive models of radiotherapy toxicity to improve quality-of-life and reduce side-effects in cancer survivors
| Coordinatore | THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.requite.eu/ |
| Totale costo | 7˙821˙718 € |
| EC contributo | 5˙997˙408 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2018-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | coordinator | 959˙167.00 |
| 2 |
UNIVERSITY OF LEICESTER
Organization address
address: University Road contact info |
UK (LEICESTER) | participant | 894˙431.00 |
| 3 |
DEUTSCHES KREBSFORSCHUNGSZENTRUM
Organization address
address: Im Neuenheimer Feld 280 contact info |
DE (HEIDELBERG) | participant | 747˙783.00 |
| 4 |
Source Bioscience plc
Organization address
address: "ORCHARD PLACE, BUSINESS PARK 1" contact info |
UK (NOTTINGHAM) | participant | 724˙000.00 |
| 5 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 637˙928.00 |
| 6 |
UNIVERSITEIT GENT
Organization address
address: SINT PIETERSNIEUWSTRAAT 25 contact info |
BE (GENT) | participant | 483˙985.00 |
| 7 |
INSTITUT REGIONAL DU CANCER DE MONTPELLIER
Organization address
address: RUE DE LA CROIX VERTE 31 PARC EUROMEDECINE contact info |
FR (MONTPELLIER) | participant | 425˙448.00 |
| 8 |
STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC
Organization address
address: Dr. Tanslaan 12 contact info |
NL (Maastricht) | participant | 237˙800.00 |
| 9 |
FUNDACION PUBLICA GALEGA DE MEDICINA XENOMICA
Organization address
city: Santiago de Compostela contact info |
ES (Santiago de Compostela) | participant | 237˙280.00 |
| 10 |
THE CHRISTIE NHS FOUNDATION TRUST
Organization address
address: WILMSLOW ROAD 1 contact info |
UK (MANCHESTER) | participant | 189˙652.00 |
| 11 |
FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI
Organization address
address: Via Venezian 1 contact info |
IT (Milan) | participant | 177˙088.00 |
| 12 |
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Organization address
address: SEMINARSTRASSE 2 contact info |
DE (HEIDELBERG) | participant | 123˙840.00 |
| 13 |
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Organization address
address: ONE GUSTAVE L LEVY PLACE BOX 1075 contact info |
US (NEW YORK) | participant | 84˙014.00 |
| 14 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 66˙592.00 |
| 15 |
UNIVERSITE DE MONTPELLIER
Organization address
address: 163 RUE AUGUSTE BROUSSONNET contact info |
FR (MONTPELLIER) | participant | 8˙400.00 |
| 16 |
UNIVERSITE MONTPELLIER I
Organization address
address: BOULEVARD HENRI IV 5 contact info |
FR (MONTPELLIER) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors. These side-effects could be reduced if predicted in advance. Previous work identified clinical and biological predictors but a major, coordinated approach is needed to validate them so they can be used clinically. The EU has ~17.8 million people living with a prior diagnosis of cancer of whom ~7 million received radiotherapy. In the long-term, potentially 20% of those suffering with mild to severe side-effects (~1.4 million) might benefit from alleviation of symptoms, with resulting reductions in the cost of care in the EU. REQUITE aims to develop validated clinical models and incorporate biomarkers to identify before treatment cancer patients at risk of side-effects and use the models to design interventional trials aimed at reducing side-effects and improving QoL in cancer survivors who underwent radiotherapy. REQUITE will: 1. carry out a multi-centre, longitudinal, observational study to collect standardised data and samples in breast, prostate and lung cancer patients; 2. validate biomarkers with published evidence of predictive value; 3. replicate published clinical models and incorporate replicated biomarkers to create validated predictive algorithms; 4. use the prospectively validated models and biomarkers to design interventional trial protocols aiming to reduce side-effects and improve QoL in high-risk patients. REQUITE builds on collaborations with a proven history of data sharing, enlarged to a consortium with expertise in patient recruitment, knowledge management, biomarker testing and predictive model development. SME involvement for biomarker assays will facilitate future clinical implementation and commercial exploitation. The outcome of this project will be validated predictive models for three common cancers and trial protocols using the models to investigate interventions aimed at reducing long-term side-effects and improving the QoL of cancer survivors.'